Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS NASDAQ:IKNA NASDAQ:INCR NASDAQ:LEXX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.50-0.3%$1.16$0.86▼$3.60$91.16M0.11295,894 shs197,880 shsIKNAIkena Oncology$1.26-1.2%$1.29$0.97▼$1.94$60.57M0.5132,591 shs294,428 shsINCRInterCure$1.53+0.3%$1.52$1.17▼$2.62$69.27M1.1818,077 shs12,468 shsLEXXLexaria Bioscience$0.95+0.4%$0.96$0.79▼$4.38$18.84M0.79147,754 shs136,246 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%+7.14%+25.00%+41.51%-47.74%IKNAIkena Oncology0.00%-7.97%-6.62%+11.40%-23.49%INCRInterCure0.00%-2.25%0.00%+12.59%-33.91%LEXXLexaria Bioscience0.00%+7.33%-1.51%-31.98%-65.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals2.7445 of 5 stars3.54.00.00.01.31.70.6IKNAIkena Oncology2.795 of 5 stars3.33.00.00.02.01.71.3INCRInterCure0.4912 of 5 stars0.03.00.00.02.00.00.6LEXXLexaria Bioscience1.7267 of 5 stars3.52.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.00Buy$6.33323.63% UpsideIKNAIkena Oncology 2.50Moderate Buy$3.00139.04% UpsideINCRInterCure 0.00N/AN/AN/ALEXXLexaria Bioscience 3.00Buy$5.00426.87% UpsideCurrent Analyst Ratings BreakdownLatest LEXX, ABOS, INCR, and IKNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.006/17/2025ABOSAcumen PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.00(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$3.03 per shareN/AIKNAIkena Oncology$9.16M6.61N/AN/A$2.61 per share0.48INCRInterCure$66.28MN/AN/AN/A$2.36 per shareN/ALEXXLexaria Bioscience$460K40.35N/AN/A$0.48 per share1.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$102.33M-$1.94N/AN/AN/AN/A-58.24%-46.53%8/12/2025 (Estimated)IKNAIkena Oncology-$49.23M-$0.86N/AN/AN/AN/A-30.59%-27.55%8/14/2025 (Estimated)INCRInterCure-$18.32MN/A0.00∞N/AN/AN/AN/A8/28/2025 (Estimated)LEXXLexaria Bioscience-$5.80M-$0.67N/AN/AN/A-1,849.19%-157.22%-133.69%N/ALatest LEXX, ABOS, INCR, and IKNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IKNAIkena Oncology-$0.14N/AN/AN/AN/AN/A8/12/2025Q2 2025ABOSAcumen Pharmaceuticals-$0.54N/AN/AN/AN/AN/A7/14/2025Q3 2025LEXXLexaria Bioscience-$0.15-$0.21-$0.06-$0.21$0.17 million$0.17 million5/13/2025Q1 2025ABOSAcumen Pharmaceuticals-$0.56-$0.48+$0.08-$0.48N/AN/A5/8/2025Q1 2025IKNAIkena Oncology-$0.21-$0.18+$0.03-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AIKNAIkena OncologyN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.198.028.02IKNAIkena OncologyN/A13.3113.31INCRInterCure0.341.731.18LEXXLexaria BioscienceN/A3.903.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%IKNAIkena Oncology75.00%INCRInterCure8.34%LEXXLexaria Bioscience13.06%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals7.10%IKNAIkena Oncology5.94%INCRInterCureN/ALEXXLexaria Bioscience26.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million56.27 millionOptionableIKNAIkena Oncology7048.26 million45.39 millionNot OptionableINCRInterCure350N/AN/AOptionableLEXXLexaria Bioscience719.56 million14.40 millionNot OptionableLEXX, ABOS, INCR, and IKNA HeadlinesRecent News About These CompaniesLEXX - Lexaria Bioscience Corp Dividends - MorningstarJuly 12, 2025 | morningstar.comMLexaria Reaches Patent Milestone - 50 Patents Now Granted WorldwideJune 23, 2025 | thenewswire.comTLexaria Reaches Patent Milestone - 50 Patents Now Granted WorldwideJune 23, 2025 | accessnewswire.comALexaria Bioscience announces completion of GLP-1-H25-5 studyJune 12, 2025 | finance.yahoo.comLexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered CapsuleJune 11, 2025 | thenewswire.comTLexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered CapsuleJune 11, 2025 | accessnewswire.comALexaria Bioscience Corp.: Lexaria Attending BIO International ConventionJune 5, 2025 | finanznachrichten.deLexaria Attending BIO International ConventionJune 5, 2025 | thenewswire.comTLexaria Attending BIO International ConventionJune 5, 2025 | accessnewswire.comALexaria Provides Update on Material Transfer Agreement with Pharmaceutical CompanyMay 12, 2025 | accessnewswire.comALexaria Provides Update on Material Transfer Agreement with Pharmaceutical CompanyMay 12, 2025 | thenewswire.comTLexaria Announces Closing of $2 Million Registered Direct Offering of Common StockApril 28, 2025 | thenewswire.comTLexaria Announces Closing of $2 Million Registered Direct Offering of Common StockApril 28, 2025 | accessnewswire.comALexaria Bioscience prices 2M shares at $1.00 in registered direct offeringApril 26, 2025 | markets.businessinsider.comLexaria Announces $2 Million Registered Direct Offering of Common StockApril 25, 2025 | accessnewswire.comALexaria Announces $2 Million Registered Direct Offering of Common StockApril 25, 2025 | thenewswire.comTLexaria provides GLP-1 update following industry developmentsApril 23, 2025 | markets.businessinsider.comRecent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s TechnologyApril 23, 2025 | finance.yahoo.comRecent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's TechnologyApril 23, 2025 | accessnewswire.comAWe Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth CarefullyApril 5, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI SpendingBest Prime Day Ever? Here Are the Prime Winners Riding the WaveBy Thomas Hughes | July 14, 2025View Best Prime Day Ever? Here Are the Prime Winners Riding the WaveSalesforce Stock Set for 30% Upside to Reach New HighsBy Thomas Hughes | July 16, 2025View Salesforce Stock Set for 30% Upside to Reach New HighsSpotify's Massive Rally: Can New Features Sustain the Momentum?By Nathan Reiff | June 27, 2025View Spotify's Massive Rally: Can New Features Sustain the Momentum?Texas Instruments Stock: Congress Likes It, Should You Too?By Thomas Hughes | June 24, 2025View Texas Instruments Stock: Congress Likes It, Should You Too?LEXX, ABOS, INCR, and IKNA Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.50 -0.01 (-0.33%) As of 12:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Ikena Oncology NASDAQ:IKNA$1.25 -0.02 (-1.18%) As of 12:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.InterCure NASDAQ:INCR$1.52 +0.01 (+0.33%) As of 12:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Lexaria Bioscience NASDAQ:LEXX$0.95 +0.00 (+0.37%) As of 12:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Q2 Could Be the Catalyst PayPal Investors Have Been Waiting For Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.